Dataset from A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (Humira®) in Chinese Subjects With Moderate to Severe Plaque Psoriasis
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.
创建时间：
2025-02-22
